RLYB - Rallybio Corp

RLYB - Rallybio Corp

https://www.rallybio.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Here's Why Shares in Recursion Pharmaceuticals Surged Today

Motley Fool • 2 months ago • score: -0.01

Shares in biotech company Recursion Pharmaceuticals ( NASDAQ: RXRX ) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline.The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program ( REV102 ) that ...

Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Rallybio ( NASDAQ:RLYB ) , Recursion Pharmaceuticals ( NASDAQ:RXRX )

Benzinga • 2 months, 1 week ago • score: 0.31

Rallybio receives $7.5 million upfront equity and is eligible for $17.5 million in future milestone payments. The cash runway is now extended into mid-2027 following the asset sale. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday ...

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - General Motors ( NYSE:GM ) , HCA Healthcare ( NYSE:HCA )

Benzinga • 5 months ago • score: 0.18

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

Zacks Commentary • 5 months ago • score: -0.18

Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.

This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Host Hotels & Resorts ( NASDAQ:HST ) , Health Catalyst ( NASDAQ:HCAT )

Benzinga • 5 months ago • score: 0.19

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keybanc analyst Paul Knight downgraded the rating for Bio-Techne Corporation TECH from ...

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints - Rallybio ( NASDAQ:RLYB )

Benzinga • 5 months ago • score: 0.01

Rallybio ended the RLYB212 FNAIT program after Phase 2 data showed drug levels failed to reach target concentration for efficacy. Dosing of RLYB116, Rallybio's C5 inhibitor, starts in Q2 2025 with PK/PD data from Cohorts 1 and 2 expected in Q3 and Q4 2025. With stocks plunging, steady income is ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$1.24

52W Low

$0.22

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-1.10

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.41

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

33.42

P/B (<3 favorable)

0.55

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

4.14%

Institutions (25–75% balanced)

74.65%

Shares Outstanding

41,786,500

Float

19,859,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

761,000

Gross Profit (TTM)

-38,633,000

EPS (TTM)

-0.93

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-47.44%

ROE (TTM) (>15% strong)

-0.66%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.29

Momentum

Bearish momentum

Value

0.0228

Previous

0.0230

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025